Zoetis appoints UC Davis Dean to Board of Directors

PARSIPPANY, N.J. - Zoetis Inc. (NYSE: ZTS), a global leader in animal health with a market capitalization of $72.27 billion, has announced the election of Dr. Mark Stetter, Dean of the University of California, Davis School of Veterinary Medicine, to its Board of Directors as of May 21, 2025. According to InvestingPro analysis, the company currently trades slightly below its Fair Value, suggesting potential upside opportunity. Dr. Stetter is expected to bring his extensive experience in veterinary medicine and animal health to the company, particularly in his new role on the Zoetis Board’s Quality and Innovation Committee.

Dr. Stetter’s career has spanned various aspects of animal health, including work with pets, livestock, exotic animals, research, and wildlife. His professional journey has taken him from The Walt Disney Company to the Wildlife Conservation Society at The Bronx Zoo and the Audubon Nature Institute before entering academia. With a strong gross profit margin of 71% and five analysts recently revising earnings estimates upward according to InvestingPro, Zoetis continues to demonstrate robust financial performance. He served as Dean and Professor at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University from 2012 until 2021, after which he took on his current role at UC Davis.

Kristin Peck, CEO of Zoetis, expressed enthusiasm for Dr. Stetter’s appointment, highlighting the value of his real-world experience and insights for the company’s mission to adapt and innovate in animal health care. Similarly, Zoetis Board Chair Michael McCallister welcomed Dr. Stetter, emphasizing the anticipated contributions to the company’s pursuit of industry advancement and customer-focused innovation.

Dr. Stetter, expressing gratitude for his new position, remarked on the impact of Zoetis’s products on animal health and his eagerness to contribute his expertise to the company’s ongoing efforts.

Zoetis, a company with a 70-year history in the animal health industry, provides products and services globally, including medicines, vaccines, diagnostics, and technologies. With a workforce of approximately 13,800 employees, Zoetis generated $9.3 billion in revenue in 2024, maintaining a 12-year streak of consecutive dividend increases. The company’s commitment to advancing care for animals is reflected in its extensive product offerings and presence in over 100 countries. InvestingPro data shows the company maintains an overall "GREAT" financial health score, with particularly strong marks in profitability and growth metrics. For deeper insights into Zoetis’s performance and potential, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

This appointment is based on a press release statement and represents a strategic move by Zoetis to enhance its board’s expertise in veterinary medicine and animal health.

In other recent news, Zoetis Inc. reported strong financial results for the first quarter of 2025, surpassing analysts’ expectations with earnings per share (EPS) of $1.48 and revenue of $2.22 billion. This performance reflects a 9% organic operational revenue growth year-over-year, driven by key product lines such as the Simparica franchise and OA pain monoclonal antibodies. Despite these positive results, UBS lowered its price target for Zoetis to $170, maintaining a Neutral rating, citing weaker-than-expected sales trends in the U.S. Librela pain franchise and global dermatology products. Meanwhile, BTIG reiterated a Buy rating with a $200 price target, highlighting Zoetis’ strong quarterly performance and potential for global market expansion. Leerink Partners also adjusted its price target to $180, maintaining an Outperform rating, while noting mixed results with strong consumer spending on parasiticides and dermatology products. The company acknowledged challenges such as potential tariff impacts and the need for improved marketing strategies for certain products. Despite these hurdles, Zoetis remains confident in its ability to sustain growth and innovation in the animal health sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.